CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 166 enrolled
Drug / intervention
Aminolevulinic Acid +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02239679
NCT02239679Phase 2Completed

A Phase 2 Study Comparing the Occurrence of Actinic Keratoses on the Face in High-Risk Individuals After Cryotherapy + Photodynamic Therapy With Levulan Topical Solution + Blue Light Versus Cryotherapy + Vehicle Topical Solution + Blue Light

DUSA Pharmaceuticals, Inc.·interventional·Posted Sep 15, 2014·Updated Aug 24, 2018

In Brief

A Phase 2 clinical trial evaluating Aminolevulinic Acid, Topical Solution Vehicle, and 2 other interventions for Actinic Keratosis. Completed, enrolled 166 participants across 8 sites.

Detailed Summary

The purpose of this study is to determine if Levulan photodynamic therapy (PDT) is safe and effective in the treatment of actinic keratoses (AK) on the face, following treatment with liquid nitrogen cryotherapy.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedSep 15, 2014
Enrollment StartSep 1, 2014
Primary CompletionJul 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.8 years ago

Interventions

Aminolevulinic Aciddrug

20% ALA applied to face for one hour prior to 10 J/cm2 blue light

Topical Solution Vehicledrug

Levulan Kerastick containing vehicle ingredients only. Vehicle solution applied to face one hour prior to 10 J/cm2 blue light

BLU-Udevice

10 J/cm2 blue light delivered at 10 mW/cm2

Cryotherapyprocedure

Liquid nitrogen cryotherapy by standard of care method to all visible/palpable actinic keratosis (AK) lesions at screening.